Launching into a crowded therapeutic category: sequencing market access, medical affairs, and commercial

Launching a drug into a crowded therapeutic category is a sequencing problem. Not a marketing problem, not a messaging problem. The order in which you deploy your functions determines whether your asset gains traction or spends three years trying to recover ground that should have been staked before approval.

Market Access Is Not a Downstream Activity

Payers in an established category are not waiting for your drug. They have formulary contracts with your competitors, rebate structures that took years to negotiate, and a clinical team that has already made peace with the options sitting on their tier. What they are waiting for is a reason to disrupt all of that, and that reason has to be constructed with data, not enthusiasm.

I have watched launch teams treat HEOR and payer advisory work as things you do in the launch year, alongside hiring sales reps and finalizing promotional materials. By the time a drug is filing for approval, a serious payer team should already know what objections are coming, because they built the health economic models, ran the advisory boards, and had the genuinely uncomfortable conversations with regional health plans eighteen months prior. Those conversations are awkward. Payers will tell you things your commercial leadership would prefer not to hear. That is the point.

If your HEOR function is being stood up simultaneously with your field force, you are already behind. Coverage gaps in the first year of a launch are rarely recoverable for a specific, structural reason: plans renew on their own calendar, not yours. Miss the formulary cycle and you are waiting another year. That year is not free.

Medical Affairs as Intelligence Infrastructure

The standard framing of medical affairs, credentialed people managing relationships at academic medical centers, undersells the function in a way that costs organizations real money. In a crowded category, the clinical community has already formed opinions. Treatment algorithms exist. There are sequencing conventions baked into practice that have nothing to do with your clinical trial data and everything to do with familiarity and institutional inertia.

Your RCT will not automatically disrupt those habits. What disrupts them is sustained, peer-to-peer scientific dialogue, conducted before launch, by people who are not legally or credibly able to promote your drug. That is the MSL's actual job in a pre-launch environment, and it takes time that cannot be compressed.

Those same MSLs are generating intelligence. They are in the field learning what physicians find genuinely inadequate about existing options, what data would actually shift prescribing behavior, and where the real unmet need lives versus where the marketing team has assumed it lives. Those two things are frequently not the same place. When there is no structured mechanism for that intelligence to flow back into commercial planning, you end up paying for a field force and leaving a substantial portion of its strategic value unrealized. The assumptions baked into your launch plan calcify. The MSLs know something your brand team does not, and no one has built the pipe to move that knowledge.

Commercial Activation Has a Moment

None of this means commercial arrives late. It means commercial arrives at the right moment.

When payers have adequate coverage in place and the clinical community has genuine scientific familiarity with your mechanism, commercial activation lands in a prepared environment. Prescribers have already encountered your drug in a clinical context before a sales rep ever walked through the door. The question in those early conversations is no longer whether your drug belongs in the treatment algorithm. It is where it fits.

That distinction matters more than it sounds. Sales force productivity in the first months of a launch has real implications for long-term market share trajectory. A commercial team launching into receptive conditions builds momentum in a way that compounds. A team launching into a market where physicians still have basic clinical questions and payers are still deliberating spends its first year in an education mode that was supposed to have happened already, on someone else's budget and timeline.

Where Organizations Actually Break Down

The sequencing failure almost never originates in strategy. It originates in org structure, and I would argue this is the thing most launch post-mortems get wrong when they reconstruct what happened.

Medical affairs, market access, and commercial typically report through different leadership chains and are budgeted separately. Each function optimizes for its own readiness metrics, its own timelines, its own internal definition of what prepared looks like. Medical affairs is demonstrating scientific activity. Market access is navigating payer relationships on a calendar driven by plan cycles. Commercial leadership is focused on headcount ramp and promotional material development. These are all legitimate activities. But without a single integrator who carries real authority across all three functions, the coordination that sequencing requires does not happen organically. It does not happen at all.

Organizations that execute well in crowded launches have solved this structurally before they solved it tactically. A cross-functional launch committee with actual decision-making authority, rather than just a forum where teams present slide updates to each other. A chief commercial officer who understands medical affairs well enough to treat it as a strategic input rather than a separate operation running on a parallel track. These are organizational prerequisites, and they have to be in place before the tactical sequencing questions are even addressable.

What I have seen, more than once, is organizations running strong functional strategies in complete isolation from one another and still losing the launch window because nobody owned the interdependencies. The plan looks coherent on paper. The execution becomes three parallel tracks that never quite converge, and by the time anyone names the problem, the formulary cycle has passed and the moment is gone.

Crowded Does Not Mean Closed

Prescribers in an established category are not uniformly satisfied with what exists. Payers are not monolithically opposed to innovation. There are patient populations underserved by current options, clinical scenarios where existing agents genuinely fall short, gaps that a well-positioned asset can occupy legitimately. The opportunity is real.

But it is only accessible to organizations that respect how formulary decisions actually get made, how clinical opinions actually form, and how commercial adoption actually builds. Sequence the functions correctly and the competitive landscape becomes context you are operating inside. Sequence them wrong, and you are spending against noise you generated by arriving in the wrong order.

The window between approval and peak commercial opportunity is finite. And it is considerably less forgiving than most launch plans assume.